TABLE 3.
GSK’254 activity against laboratory strains
| Virus | GSK’254 EC50 ± SD, nMa | GSK’795 EC50 ± SD, nMb |
|---|---|---|
| HIV-1 T tropic | ||
| RF | 0.9 ± 0.15 | 6.9 ± 2.8 |
| IIIB | 0.6 ± 0.40 | 2.5 ± 0.8 |
| HXB2 | 0.7 ± 0.10 | 9.3 ± 3.9 |
| NL4-3 | 0.9 ± 0.20, 7.3b | 3.9 ± 2.2, 19 |
| LAI | 0.7 ± 0.10 | 2.4 ± 0.8 |
| MN | 0.3 | 1.0 |
| HIV-1 M tropic | ||
| Bal | 1.1c | 3.7c |
| JRFL | 1.2c | 13c |
| HIV-2 | ||
| ROD | >3,000, 2.5b | >3,000, 17 |
| 287 | 1,245, >1,386b | 751 |
a
Activity determined through inhibition of luciferase activity in CEM-NKR-CCR5-Luc cells unless otherwise noted.
b
Activity determined through inhibition of reverse transcriptase activity in MT-2 cells unless otherwise noted.
c
Activity determined through inhibition of p24 in PM1 cells.